Abstract

PPD02.02 Tepotinib + Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract CT538: Tepotinib + gefitinib in patients with EGFR-mutant NSCLC with MET amplification: Final analysis of INSIGHT
Chong Kin Liam ... Jianying Zhou
American Journal of Cancer | VOL. 82
Chong Kin Liam, et. al.Chong Kin Liam ... Jianying Zhou
15 Jun 2022
477O - Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study
K Park ... Y.-L Wu
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 30
K Park, et. al.K Park ... Y.-L Wu
01 Nov 2019
P3.02b-051 Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study: Topic: EGFR Clinical
Simon Baldacci ... Alexis Cortot
Journal of Thoracic Oncology | VOL. 12
Simon Baldacci, et. al.Simon Baldacci ... Alexis Cortot
31 Dec 2016
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
...
The Lancet Respiratory Medicine | VOL. 8
, et. al. ...
29 May 2020
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
From the IASLC Early Detection and Screening Committee Terminology Issues in Screening and Early Detection of Lung Cancer – IASLC Early Detection and Screening Committee Expert Group Recommendations
Rudolf M Huber ... Rudolf Huber
Journal of Thoracic Oncology | VOL. -
Rudolf M Huber, et. al.Rudolf M Huber ... Rudolf Huber
02 Aug 2024
Real-world acute toxicity and 90-day mortality in patients with stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Peter S.N Van Rossum ... José S.A Belderbos
Journal of Thoracic Oncology | VOL. -
Peter S.N Van Rossum, et. al.Peter S.N Van Rossum ... José S.A Belderbos
25 Jul 2024
Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC
Soyeong Jun ... Maximilian Diehn
Journal of Thoracic Oncology | VOL. -
Soyeong Jun, et. al.Soyeong Jun ... Maximilian Diehn
05 Jul 2024
PP01.95 STK11, KEAP1, and KRAS mutation epidemiology and real-world outcomes in US patients with newly diagnosed metastatic non-small cell lung cancer
Firas Dabbous ... Ferdinandos Skoulidis
Journal of Thoracic Oncology | VOL. 19
Firas Dabbous, et. al.Firas Dabbous ... Ferdinandos Skoulidis
01 Jul 2024
View more papers